Ice-breaking Ipo U.s. Biotech Industry Rebound - Biotechnology, The U.s. Ipo-pharmaceutical

Last year, the U.S

Last year, the U.S. IPO market can be said that the U.S. capital market history, the worst year, so this year's market is?

So far this year, the capital market only 31 IPO companies to submit a formal application, the applicant for the same period last year 63% less, be listed since 2003, the slowest pace of the year.

However, the health industry-related market is not too bad. Listed companies in making the application, the bio-technology companies accounted for about one-third.

How many homes can be successfully listed, and now difficult to estimate, but at least not be as bleak.

Favored by the Health Industry

2 months, Bristol-Myers Squibb's nutrition and health care products companies divest MeadJohnson market success, raising 8.28 billion dollars, a good market response.

6 months, a clinical trial data management company MedidataSolutions IPO, raising capital 100 million U.S. dollars, sought after by the market.

7 months, the Shanghai company called ChemSpec a successful IPO in New York. The company was founded in 1996, is a chemical API And Intermediate Company, 2008 Sell Amounted to 138,000,000 U.S. dollars, profit of 45 million U.S. dollars. The company has Eli Lilly and Merck and other large customers, the current capacity of 110 million liters Reactor This year will expand to 280 million liters. The company successfully raised through ADR 75 million U.S. dollars.

8 months, there are two companies that concern the health industry: characteristics drug maker Cumberland (Cumberland) is available now; Electronic Medical company Emdeon ready market clearing system.

Cumberland Pharma will seek to raise 100 million U.S. dollars. The company has two products on the market: the intravenous injection Caldolor ibuprofen and acetaminophen for the treatment of excessive Acetadote. The latter just in time, because the U.S. FDA recently increased supervision, warning people to attach importance to paracetamol overdose caused harm.

Market Emdeon electronic medical billing companies showed interest, because the Obama administration is vigorously promoting the health information. According to "The Wall Street Journal" reported, in 2008, Emdeon handling nearly half of the U.S. electronic medical claims, the company hopes to raise its initial public offering of 332.5 million U.S. dollars to.

Ice biotechnology industry

In addition, there are biotech companies gearing up for the upcoming launch of the IPO market for a final push of preparations. The further development of this trend, it is possible to encourage a number of venture capital invested in more new drug development companies and biotechnology companies.

Some analysts believe that, IPO window re-opening indication of the desire to fund biotechnology companies can be described as "long drought every dew." Biotechnology Industry Organization BIO and Thomson Reuters According to recent market conditions, infer the biotechnology industry began to clear signs of recovery.

Investors more optimistic about a number of exciting clinical trial data, driving more than biotechnology company's stock rising, analysts say an investment in this year's annual survey of market analysis is also generally tended to show positive attitude. However, there are some investors still cautious optimistic because they believe that between 2009 and 2011, the overall efficiency of R & D is only equivalent to the situation from 2006 to 2008.

"We are encouraged by the field of biotechnology is beginning to recover." Thomson Reuters global head of investor relations services Bill

Haney pointed out that given the current economic situation, the company's CEO and CFO must always keep in touch with the investment community and contact and frank description of their goals, plans and achievements. "However, the biotechnology company's senior management has been proactive in communicating with the media straight up."

Now more and more obvious signs of improvement, investment banks are actively encouraging more behind the listing of biotechnology companies. The first half of 2010 there will be many listed companies waiting in line. Perhaps by that time, the IPO market will recover fully. To go through this winter biotechnology company, may be able to catch up with the next wave of capital market heat.

To be high quality of listed companies

Starting in 2008, investors were very cold on the IPO. Last fall with the economic turmoil Financial Market downturn, making totally paralyzed IPO market, venture capital, therefore the main exit channel completely closed.

Now, IPO window has finally opened. Many institutional investors want to see the IPO again to pick up, because many companies want to market their venture capitalists also hope behind the smooth exit.

by: gaga

POST COMMENT

Discover - Restarting Natural Growth At Any Age - Enhancement Techniques Which Add Inches Welding Through Pre-heating And Cooling Technique Biosphere technology Introduction Roving Machine-made Breakthroughs Made In Key Technologies - China Finger Splint The Latest Hearing Aids Supported with Wireless Bluetooth Technology Connecting Technology - Micro USB Convert jpeg to text using OCR technology 2 Easy To Understand Techniques To Successfully Get a Tremendous and Vibrant Male Member Facts on the Newest Keyboard Technology and Costs Safe And Natural Rug Cleaning Techniques new technology of nitrogen generator Vibrating Mesh Technology And How It Changed The Nebulizer Device When L Technology: Li-ion Battery Experts Lead A Low Carbon Economy